High H pylori Eradication Rate with Rifabutin-Based Therapy
A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.
Bacterial Infections
Revised Clostridioides difficile Practice Guidelines Had Significant Effect on Treatment Decisions
Publication of the revised clinical practice guidelines for Clostridioides difficile infection was followed by significant increases in use of oral vancomycin and fidaxomicin, and a significant decrease in use of oral metronidazole.
COVID-19 Superinfections and Antimicrobial Resistance
Epidemiologic, clinical, microbiologic and antimicrobial resistance (AMR) data on nosocomial superinfections during the coronavirus disease 2019 (COVID-19) pandemic is needed to inform stewardship.
Microbiome-Based Therapy Looks Promising for Recurrent C Difficile Infection
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
Brucella-Associated Endocarditis in People who Inject Drugs
Two cases of endocarditis as a result of Brucella have been reported in people who inject drugs without zoonotic exposure.
RHB-105 Effective for Eradication of Helicobacter pylori in Adults
A novel rifabutin-based triple therapy (RHB-105) is effective for eradication of Helicobacter pylori, with eradication rates unaffected by resistance to clarithromycin or metronidazole.
Developing New Antimicrobial Resistance From Medical Devices Is Rare
The concern for development of new resistance to central lines coated with antimicrobial combinations was not validated by current clinical and experimental evidence.
Incidence of Enteric Infections Due to Pathogens Increased or Stable
In 2019, the incidence of enteric infections caused by eight pathogens increased or remained stable.
National Burden of C difficile Infection Decreased From 2011 Through 2017
As a result of a decline in healthcare–associated infections, the estimated burden of Clostridioides difficile infection in the United States decreased by an adjusted 24% from 2011 through 2017.
Linezolid-Containing Regimen as Empiric Treatment for Moderate to Severe Nocardiosis
Linezolid use in combination therapy is effective and as safe as other firstline treatments for moderate to severe nocardiosis.
-
Loading...
-
Loading...
Next post in Respiratory
